SACT-1 + EDURANT 25Mg Tablet

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 19/100
19
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Healthy Subject

Conditions

Healthy Subject

Trial Timeline

Oct 9, 2021 → Dec 14, 2021

About SACT-1 + EDURANT 25Mg Tablet

SACT-1 + EDURANT 25Mg Tablet is a phase 1 stage product being developed by Aptorum Group for Healthy Subject. The current trial status is completed. This product is registered under clinical trial identifier NCT05358756. Target conditions include Healthy Subject.

What happened to similar drugs?

20 of 20 similar drugs in Healthy Subject were approved

Approved (20) Terminated (1) Active (0)

Hype Score Breakdown

Clinical
6
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05358756Phase 1Completed

Competing Products

20 competing products in Healthy Subject

See all competitors
ProductCompanyStageHype Score
Use of Wearable Digital Sensors After mRNA Vaccination in AdultsModernaPreclinical
0
mRNA-0184ModernaPhase 1
0
mRNA-6231ModernaPhase 1
0
LetrozoleDr. Reddy's LaboratoriesPhase 1
26
IsotretinoinDr. Reddy's LaboratoriesPhase 1
26
FexofenadineDr. Reddy's LaboratoriesPhase 1
26
SertralineDr. Reddy's LaboratoriesPhase 1
26
Nizatidine + AxidDr. Reddy's LaboratoriesPhase 1
26
AnastrozoleDr. Reddy's LaboratoriesPhase 1
26
mRNA-1273.712ModernaApproved
0
RisperidoneDr. Reddy's LaboratoriesPhase 1
26
LamotrigineDr. Reddy's LaboratoriesPhase 1
26
Metformin + GlucophageDr. Reddy's LaboratoriesPhase 1
26
LamotrigineDr. Reddy's LaboratoriesPhase 1
26
mRNA-0184ModernaPhase 1
0
Divalproex SodiumDr. Reddy's LaboratoriesPhase 1
26
SirolimusDr. Reddy's LaboratoriesPhase 1
26
GlimepirideDr. Reddy's LaboratoriesPhase 1
26
Ziprasidone HydrochlorideDr. Reddy's LaboratoriesPhase 1
26
Naproxen sodiumDr. Reddy's LaboratoriesPhase 1
26